These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 33531827)

  • 1. Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance.
    Keinath MC; Prior DE; Prior TW
    Appl Clin Genet; 2021; 14():11-25. PubMed ID: 33531827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
    Aslesh T; Yokota T
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
    Li Y; Zeng H; Wei Y; Ma X; He Z
    Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy.
    Kotulska K; Fattal-Valevski A; Haberlova J
    Front Neurol; 2021; 12():726468. PubMed ID: 34721262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Spinal Muscular Atrophy].
    Ishiyama A
    Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
    Hjartarson HT; Nathorst-Böös K; Sejersen T
    Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).
    Wirth B
    Hum Mutat; 2000; 15(3):228-37. PubMed ID: 10679938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
    Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
    Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
    Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model.
    Son YS; Choi K; Lee H; Kwon O; Jung KB; Cho S; Baek J; Son B; Kang SM; Kang M; Yoon J; Shen H; Lee S; Oh JH; Lee HA; Lee MO; Cho HS; Jung CR; Kim J; Cho S; Son MY
    Stem Cells Dev; 2019 Apr; 28(7):438-453. PubMed ID: 30667343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.
    Chiriboga CA
    Paediatr Drugs; 2022 Nov; 24(6):585-602. PubMed ID: 36028610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy.
    Edinoff AN; Nguyen LH; Odisho AS; Maxey BS; Pruitt JW; Girma B; Cornett EM; Kaye AM; Kaye AD
    Orthop Rev (Pavia); 2021; 13(2):24934. PubMed ID: 34745470
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.